June 2020 ITOG
Quarterly Update E-Newsletter

Executive Committee

Manisha H. Shah, MD, Chair
The Ohio State University
Sareh Parangi, MD, Secretary
Harvard Medical School
Eric Sherman, MD Chair, Protocol Committee
Memorial Sloan-Kettering Cancer Center
Dwight Vicks III MBA, Treasurer
President, Vicks, Inc.

Board of Directors
Keith C. Bible, M.D., Ph.D.
Mayo Clinic (Rochester)
Naifa Busaidy, MD
MD Anderson Cancer Center
Maria Cabanillas, MD
MD Anderson Cancer Center
James Fagin, MD
Memorial Sloan-Kettering
Andrew Gianoukakis, MD
University of California, Los Angeles
Elizabeth Grubbs, MD
MD Anderson Cancer Center
Bryan Haugen, MD
University of Colorado, Health Sciences Center
Alan Ho MD, PhD
Memorial Sloan-Kettering
Sophie Leboulleux
Gustave Roussy
Gregory Randolph, MD
Massachusetts Eye and Ear Infirmary
Bruce G. Robinson, MD
University of Sydney
Julie Ann Sosa, M.D.
University of California, San Francisco

Message from the Chair

Manisha Shah, MD
Dear Friends,
I sincerely hope that you and your families...
are safe during COVID-19 pandemic. This pandemic has fundamentally changed how we interact with patients and each other, but it has not stopped our commitment and hard work at the ITOG. Our Board of Directors, Committees and Task Forces at ITOG continue to meet using video conferencing services.

I am thrilled to share your excitement about achieving a great mile-stone in Management of RET-mutated Medullary Thyroid Cancer and RET-fusion Thyroid Cancer as Selpercatinib (LOXO-292) was approved by Food and Drug Administration (FDA) on May 8 2020 for these indications. Please join me in congratulating incredible work, dedication and diligence of numerous members of ITOG for a pivotal international clinical trial leading to such a historic moment. I am excited to present (virtually) updates of this trial at the American Society of Clinical Oncology (ASCO) Annual meeting later this month.

Furthermore, both ongoing investigator-initiated clinical trials led by Drs. Alan Ho and Bryan Haugen at ITOG met the target accrual goals and results of one of such trials are being presented by Dr. Bryan Haugen at upcoming ASCO Annual meeting. Protocol committee and Task Forces are working hard to build on this momentum to develop new trials to aid in catalyzing a cure for Thyroid Cancer. I urge you to continue your dedication and contribution to ongoing ITOG trials.

Finally, I am excited to announce that we are opening the Nominations and Elections Process today for five (5) Board of Director-At-Large open Positions. Current members in good standing, including past Board of Directors are eligible to apply. Interested candidates may be nominated or self-nominated. This is a great opportunity to contribute to ITOG’s direction and future. We are extending the nomination and voting time frame to ensure that all members have ample time to participate.

If you would like to submit a nomination please see information below!

ITOOG TOP NEWS

FDA Approval for Retevmo (selpercatinib)

Based on the clinical trial results from the LIBRETTO-001 (NCT03157128) Phase 1/2 trial in RET-altered thyroid cancer, Retevmo™ (selpercatinib) is now
approved to treat advanced medullary thyroid cancer (MTC) ...

ACCRU-ITOG-1504 Achieves Accrual Goal

Congratulations to Principal Investigator: Bryan Haugen at The University of Colorado Cancer Center and his team for achieving accrual goal of 60 ACCRU-ITOG-1504: Combination Targeted Therapy with Pembrolizumab and Lenvatinib in Progressive, Radioiodine-Refractory Differentiated Thyroid Cancers: A Phase II Study.

ITOG Active Clinical Trials

ACCRU/ITOG 1504 Combination Immunotherapy with Multikinase Inhibitor (MKI) in Progressive, Radioiodine-resistant Differentiated Thyroid Cancers
Accrual Status: Closed to Accrual
Accrual Goal: 60
Current Accrual: 60

**PI:** Bryan Haugen, MD  University of Colorado Cancer Center

**Selumetinib Rius RAI for RAI-Avid Thyroid Cancers**
Accrual Status: Closed to Accrual
Accrual Goal: 60
Current Accrual: 60

**PI: Alan Ho, MD.** Memorial Sloan-Kettering Cancer Center

**Phase 1/2 Study of LOXO-292 in Patients With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer(LIBRETTO- 001)**
Accrual Status: Accruing

**PI: Lori Wirth, MD Massachusetts General Hospital**

**Testing the Combination of Cabozantinib, Nivolumab, and Ipilimumab (CaboNivoIpi) for Advanced Differentiated Thyroid Cancer**
Accrual Status: Accruing

**Bhavana Konda, MD, MPH.** Ohio State University

**Dabrafenib, Trametinib, and IMRT in Treating Patients With BRAF Mutated Anaplastic Thyroid Cancer**
Accrual Status: Estimated to open for accrual June 2020

**PI: Manisha Shah, MD.** Ohio State University

**ITOG MEMBERS CORNER**

**ITOG Board of Directors - Call for Nominations opens today**

**Five (5) Board of Director-At-Large Positions**
The ITOG Board of Directors invites the general membership to nominate members who are qualified and dedicated to the mission of this organization, to serve on the Board of Directors. The term of members of the Board of Directors is three years, commencing June 2020.

There are currently five (5) Board of Director-At-Large Positions open for nomination.

The Best Resource for ITOG News is YOU!

We need your help to generate current, engaging content for the ITOG website. To facilitate this process, you can simply email a quick draft mailto:itog.npl@gmail.com or idea to our in-house scientific writer, who will edit or write copy that will be reviewed and published to our site. Please share the following for publication on the ITOG website:

- Thyroid Cancer News and Breakthroughs
- Clinical Trials
- Publications, Presentations
- Grants
- Awards and Acknowledgements
- Promotions and Retirements
- Meetings and Events
- Industry News
- Fundraising
- Patient Stories
- ITOG Announcements and Updates
- Photographs

Click Below to Submit News Item

Have You Updated your ITOG Membership Profile?

As a member, you will find access to our Member Directory, Community Forum, and Members Only information, including ITOG Clinical Trial Updates.
ITOG Members are making an impact on our mission to "Catalyze a Cure for Thyroid Cancer" and you can read about them here.

Paying your Membership

Making a Donation?

Credit Cards Now Accepted Online

We are proud to announce that ITOG website now accepts credit cards in addition to PayPal for membership dues and donations.